The University of Sheffield
Department of Cardiovascular Science

Professor Anne Goodeve BSc PhD

Professor of Molecular Medicine

Dr. Anne Goodeve

Department of Cardiovascular Science
University of Sheffield
Medical School
Beech Hill Road
S10 2RX

Telephone: +44 (0)114 271 2679 / 271 7005
Fax: +44 (0)114 271 1863

Secretary: Mrs Yvonne Steel
Telephone: +44 (0)114 271 2587


I joined the University of Sheffield in 2001, having previously been closely associated with the organisation for several years as an honorary lecturer. My background is in molecular biology and genetics of haematological disorders. Following a PhD and postdoctoral position working on a viral genetics, I began investigation of the molecular pathogenesis of inherited haemostatic disorders in 1990 and spend my time equally between the University and on diagnostic aspects of this work at Sheffield Diagnostic Genetics Service.

Research Interests:

My work is aimed at understanding the pathogenesis of the inherited bleeding disorder, von Willebrand disease. Current work is focussed on determination of the contribution of genetic variation in the von Willebrand factor (VWF) gene, ABO blood group and other non-VWF loci on low plasma VWF level and symptoms of bleeding.

Current Projects:

Zimmerman Program on the Molecular and Clinical Biology of von Willebrand Disease, a National Institute for Health funded Program Project Grant in collaboration with Bob Montgomery, Milwaukee and David Lillicrap, Kingston Ontario.

Professional Activities:

Key Publications:

  1. Perry DJ, Cumming T, Goodeve A, Hill M, Jennings I, Kitchen S, Walker I. The UK National External Quality Assessment Scheme for heritable bleeding disorders. Semin Thromb Hemost. 2014; 40: 261-8.

  2. Castaman G, Goodeve A, Eikenboom J, European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013; 98: 667-74.

  3. Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gursel T, Ingerslev J, Peake IR, Goodeve AC. Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thromb Haemost. 2013; 110: 264-74.

  4. Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013; 121: 2336-9.

  5. Goodeve A, Peake I. Laboratory analysis of von Willebrand disease: Molecular analysis. In: Quality in Laboratory Hemostasis and Thrombosis, Second edition. Kitchen S, Preston FE, Olson JD (Eds), Wiley-Blackwell, Chichester UK, 2012.

  6. Cooper PC, Goodeve AC, Beauchamp NJ. Quality in molecular biology testing for inherited thrombophilia disorders. Sem Thromb Haemost. 2012; 38: 600-12.

  7. Hampshire DJ, Goodeve AC. The international society on thrombosis and haematosis von Willebrand disease database: an update. Sem Thromb Haemost 2011; 37: 470-9.

  8. James PD, Goodeve AC. von Willebrand disease. Genet Med 2011; 13: 365-76.

  9. Goodeve AC, Reitsma PH, McVey JH, On behalf of the Working Group on Nomenclature of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Nomenclature of genetic variants in hemostasis. J Thromb Haemost 2011; 9: 852-5.

  10. Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P, Peake I, Eikenboom J, Goodeve A. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. J Thromb Haemost 2010; 8: 1986–93.

  11. Hampshire DJ, Burghel GJ, Goudemand J, Bouvet LC, Eikenboom JC, Schneppenheim R, Budde U, Peake IR, Goodeve AC. Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. Haematologica 2010; 95: 2163-5.

  12. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-34.

  13. Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009; 7: 1304-12.

  14. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008; 111: 3531-9.

  15. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007; 109: 112-21.

Search PubMed:   

PubMed Logo